HCPCS Code J9177: Injection, Enfortumab Vedotin-Ejfv, 0.25 mg

J9177 is defined as Injection, enfortumab vedotin-ejfv, 0.25 mg. Report units in 0.25 mg increments corresponding exactly to the dose administered from a single-dose vial.

Enfortumab vedotin is an antibody–drug conjugate used as targeted therapy for urothelial cancer.

Mechanistically, an enfortumab injection is targeted therapy (an antibody–drug conjugate). For coding and administration, many payers treat it under chemotherapy administration rules (e.g., 96413/96415) for locally advanced or metastatic disease. Bladder-sparing approaches aimed at a preserved bladder are distinct and typically apply to localized settings, not metastatic treatment courses.